

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.
百濟神州有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 06160)

RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGES OF NOMINATING AND CORPORATE GOVERNANCE COMMITTEE, SCIENTIFIC ADVISORY COMMITTEE, AND COMMERCIAL AND MEDICAL AFFAIRS ADVISORY COMMITTEE

BeiGene, Ltd. (the “**Company**”) announces that Mr. Jing-Shyh (Sam) Su (“**Mr. Su**”) resigned as an independent non-executive director on January 31, 2022, and Dr. Margaret Han Dugan and Dr. Alessandro Riva have been appointed to the board of directors of the Company (the “**Board**”) as independent non-executive directors, effective as of February 1, 2022.

Resignation of Independent Non-Executive Director

On January 31, 2022, Mr. Su resigned from the Board. In connection with his resignation from the Board, Mr. Su also resigned from the Nominating and Corporate Governance Committee and the Commercial and Medical Affairs Advisory Committee of the Board. Mr. Su served as a member of the Board since 2018. The decision by Mr. Su to resign was not the result of any disagreement with respect to the operations, policies, or practices of the Company. There is no matter in respect of Mr. Su’s resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Su for his invaluable contribution to the Company during his tenure of office.

Appointment of Independent Non-Executive Directors

On February 1, 2022, the Board was enlarged from 11 to 12 members. The Board appointed Dr. Margaret Han Dugan (“**Dr. Dugan**”) and Dr. Alessandro Riva (“**Dr. Riva**”) to fill the two vacancies arising from the resignation of Mr. Su and the enlargement of the size of the Board. Each of Drs. Dugan and Riva will serve as an independent non-executive director and Class I director until the 2022 annual general meeting of Shareholders to be held in June 2022 and until her or his successor is duly elected and qualified, subject to her or his earlier resignation or removal.

In addition, Dr. Dugan was appointed to serve as a member of the Scientific Advisory Committee of the Board. Dr. Riva was appointed to serve as a member of the Nominating and Corporate Governance Committee and the Scientific Advisory Committee of the Board.

Set out below is the biography of each of Drs. Dugan and Riva and other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

Dr. Dugan, aged 65, is currently Chief Medical Officer at Dracen Pharmaceuticals, Inc., a privately held pharmaceutical company based in New York that leverages immuno-metabolism in oncology. She joined Dracen in 2018 with more than 20 years of experience in oncology. From 1998 to 2018, Dr. Dugan held senior leadership roles at Novartis Oncology, including Senior Vice President and Global Program Head, developing innovative medicines for patients. Prior to that, Dr. Dugan held several development positions at Schering-Plough (now Merck & Co.) and American Cyanamid (now Pfizer). Dr. Dugan received her Bachelor of Arts and medical degrees and training in hematology and oncology from New York University. We believe that Dr. Dugan’s extensive scientific and leadership experience in the healthcare sector qualifies her to serve on, and contributes to the diversity of, the Board.

Dr. Riva, aged 61, is currently Chief Executive Officer of Intima Bioscience, Inc., a privately held clinical stage gene and cell therapy company. From 2019 to 2021, he served as Chief Executive Officer at privately held Ichnos Sciences, where he built a biotechnology company focused on bi- and tri-specific antibodies in oncology and biologics in autoimmune diseases. From 2017 to 2019, he was Executive Vice President and Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma. Prior to Gilead, from 2005 to 2016, Dr. Riva was Executive Vice President and Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals, where he contributed significantly to the Oncology Business Unit and Gene Therapy Unit. He was also interim President of Novartis Oncology during the acquisition of GSK Oncology. Dr. Riva is currently on the board of directors of Century Therapeutics, Inc., a NASDAQ-listed biotechnology company developing innovative iPSC-derived NK and T cell therapies. He previously held roles at Farmitalia Carlo Erba, Rhône-Poulenc Rorer and Aventis and co-founded the Breast Cancer International Research Group (BCIRG) and the Cancer International Research Group (CIRG), where he served as Chief Executive Officer. He received his M.D. in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution. We believe that Dr. Riva’s extensive scientific and management experience in the healthcare sector qualifies him to serve on, and contributes to the diversity of, the Board.

There is no service contract between the Company and Drs. Dugan and Riva. Drs. Dugan and Riva will receive the same compensation and indemnification as the Company’s other independent non-executive directors, as described in the Company’s proxy statement/circular for its 2021 annual general meeting of Shareholders filed with the United States Securities and Exchange Commission on April 30, 2021 and the Stock Exchange on May 3, 2021, respectively. In accordance with the Company’s amended independent director compensation policy (the “**Policy**”) and Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the “**2016 Plan**”), the Company will grant each of Drs. Dugan and Riva a share option valued at US\$400,000, pro-rated in the first year of service, with an exercise price equal to the greater of (i) the fair market value of the Company’s ordinary shares on the date of grant and (ii) the average fair market value of the Company’s ordinary shares over the five trading days preceding the date of grant, in each case as determined in reference to the closing price of the Company’s American Depositary Shares (“**ADSs**”) on the NASDAQ Stock Market. Each ADS represents 13 ordinary shares. The share option will vest in full on the earlier of the first anniversary of date of grant or the date of the next annual general meeting of Shareholders, and in full upon death, disability or the occurrence

of specified events in connection with a change of control of the Company. Dr. Dugan will also receive annual cash compensation of US\$60,000 for her service as an independent director, and annual cash compensation of US\$9,000 for her service as a member of the Scientific Advisory Committee, each pro-rated in the first year of service, and reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and its committees. Dr. Riva will also receive annual cash compensation of US\$60,000 for his service as an independent director, annual cash compensation of US\$7,500 for his service as a member of the Nominating and Corporate Governance Committee, and annual cash compensation of US\$9,000 for his service as a member of the Scientific Advisory Committee, each pro-rated in the first year of service, and reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and its committees. Additionally, Drs. Dugan and Riva will be entitled to future cash compensation and annual equity grants in accordance with the Policy and the 2016 Plan.

Except as disclosed above, Drs. Dugan and Riva (i) do not hold any other position in the Company or any subsidiaries of the Company; (ii) have not held in the last three years any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) do not have any relationships with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) do not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as of the date of this announcement.

Except as disclosed above, there is no information that should be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules and there are no other matters concerning the appointment of Drs. Dugan and Riva that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Company would like to extend its warm welcome to Drs. Dugan and Riva on their new appointments.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, February 4, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Mr. Timothy Chen, Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, and Mr. Qingqing Yi as Independent Non-executive Directors.